LU91131I2 - Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine. - Google Patents
Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.Info
- Publication number
- LU91131I2 LU91131I2 LU91131C LU91131C LU91131I2 LU 91131 I2 LU91131 I2 LU 91131I2 LU 91131 C LU91131 C LU 91131C LU 91131 C LU91131 C LU 91131C LU 91131 I2 LU91131 I2 LU 91131I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- duloxetine
- pharmaceutically acceptable
- acid addition
- addition salts
- acceptable acid
- Prior art date
Links
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229960002866 duloxetine Drugs 0.000 title 1
- 229960002496 duloxetine hydrochloride Drugs 0.000 title 1
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94512286A | 1986-12-22 | 1986-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU91131I2 true LU91131I2 (fr) | 2005-03-29 |
Family
ID=25482649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91131C LU91131I2 (fr) | 1986-12-22 | 2005-01-26 | Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0273658B1 (fr) |
| JP (1) | JP2549681B2 (fr) |
| KR (2) | KR880007433A (fr) |
| CN (1) | CN1019113B (fr) |
| AR (1) | AR243868A1 (fr) |
| AT (1) | ATE57924T1 (fr) |
| AU (1) | AU591007B2 (fr) |
| CA (1) | CA1302421C (fr) |
| CY (2) | CY1682A (fr) |
| DE (3) | DE122005000002I1 (fr) |
| DK (1) | DK174599B1 (fr) |
| EG (1) | EG18230A (fr) |
| ES (1) | ES2019949B3 (fr) |
| GR (1) | GR3001207T3 (fr) |
| HK (1) | HK69693A (fr) |
| HU (1) | HU206309B (fr) |
| IE (1) | IE873449L (fr) |
| IL (1) | IL84863A (fr) |
| LU (1) | LU91131I2 (fr) |
| MX (1) | MX9845A (fr) |
| NL (1) | NL300171I2 (fr) |
| NZ (1) | NZ222980A (fr) |
| PH (1) | PH26556A (fr) |
| PT (1) | PT86389B (fr) |
| SG (1) | SG114992G (fr) |
| SU (1) | SU1598865A3 (fr) |
| ZA (1) | ZA879472B (fr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| CA2042346A1 (fr) * | 1990-05-17 | 1991-11-18 | Michael Alexander Staszak | Synthese chirale de 1-aryl-3-aminopropan-1-ols |
| EP0571685A1 (fr) * | 1992-05-27 | 1993-12-01 | Novo Nordisk A/S | Aryloxyhétéroaryle propylamines, leur préparation et leur utilisation |
| US5362886A (en) * | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| GB0004149D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| GB0004153D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| GB0004152D0 (en) * | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| GB0004151D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| MXPA04000979A (es) * | 2001-07-31 | 2005-02-17 | Upjohn Co | Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas. |
| SE0102640D0 (sv) | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| EP2316469A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
| WO2003078418A1 (fr) * | 2002-03-19 | 2003-09-25 | Mitsubishi Chemical Corporation | Compose de 3-hydroxy-3-(2-thienyl)propionamide, procede de fabrication correspondant, et procede de fabrication d'un compose de 3-amino-1-(2-thienly)1-propanol a partir de ce dernier |
| US7659409B2 (en) | 2002-03-19 | 2010-02-09 | Mitsubishi Chemical Corporation | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same |
| EP1506965A4 (fr) * | 2002-05-20 | 2010-11-03 | Mitsubishi Rayon Co | Derives de propanolamine, procede de preparation de 3-n-methylamino-1-(2-thienyl)-1-propanols et procede de preparation de derives de propanolamine |
| DE10235206A1 (de) | 2002-08-01 | 2004-02-19 | Basf Ag | Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| GB0229583D0 (en) | 2002-12-19 | 2003-01-22 | Cipla Ltd | A process for preparing duloxetine and intermediates for use therein |
| DE10302595A1 (de) | 2003-01-22 | 2004-07-29 | Basf Ag | 3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung |
| DE10345772A1 (de) | 2003-10-01 | 2005-04-21 | Basf Ag | Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol |
| DE102004004719A1 (de) | 2004-01-29 | 2005-08-18 | Basf Ag | Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen |
| WO2005080370A1 (fr) * | 2004-02-19 | 2005-09-01 | Lonza Ag | Procede de preparation de 3-aminoalcools 1-substitues enantiomeriquement purs |
| RU2330012C2 (ru) * | 2004-02-20 | 2008-07-27 | Фармация Энд Апджон Компани Ллс | Способ получения простых ариловых эфиров |
| DE102004022686A1 (de) | 2004-05-05 | 2005-11-24 | Basf Ag | Verfahren zur Herstellung optisch aktiver Alkohole |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| EP1784381A1 (fr) | 2004-08-26 | 2007-05-16 | Neurosearch A/S | Nouvelles aryloxy-alkylamines substituees et leur utilisation comme inhibiteurs du recaptage du neurotransmetteur monoamine |
| JP2007523213A (ja) * | 2004-12-23 | 2007-08-16 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法 |
| MX2007011255A (es) | 2005-03-14 | 2007-10-18 | Teva Pharma | Clohidrato de duloxetina puro. |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| WO2007011820A2 (fr) | 2005-07-15 | 2007-01-25 | Amr Technology, Inc. | Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine |
| DE102005044736A1 (de) | 2005-09-19 | 2007-03-22 | Basf Ag | Neue Dehydrogenasen, deren Derivate und ein Verfahren zur Herstellung von optisch aktiven Alkanolen |
| WO2007038253A2 (fr) * | 2005-09-22 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Dnt-maleate, procedes de preparation de dernier |
| ITMI20051970A1 (it) | 2005-10-18 | 2007-04-19 | Solmag S P A | Processo per la preparazione di eteri misti derivanti dall'inaftolo e intermedi di forme cristalline definite di + e - duloxetina |
| ES2329413T3 (es) * | 2005-11-30 | 2009-11-25 | F. Hoffmann-La Roche Ag | 3-amino-2-arilpropil azaindoles y usos de los mismos. |
| WO2007067581A1 (fr) | 2005-12-05 | 2007-06-14 | Teva Pharmaceutical Industries Ltd. | 2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| DE102005062662A1 (de) | 2005-12-23 | 2007-06-28 | Basf Ag | Verfahren zur Herstellung optisch aktiver Alkohole |
| DE102005062661A1 (de) | 2005-12-23 | 2007-08-16 | Basf Ag | Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol |
| CZ299270B6 (cs) | 2006-01-04 | 2008-06-04 | Zentiva, A. S. | Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu |
| EP1976844A4 (fr) | 2006-01-06 | 2010-11-03 | Msn Lab Ltd | Procede ameliore pour la preparation de chlorhydrate de duloxetine |
| EP2114912B1 (fr) | 2006-12-22 | 2012-04-04 | Synthon B.V. | Procede de fabrication de la duloxetine et de composes apparentes |
| CN101998866A (zh) * | 2008-04-11 | 2011-03-30 | 尼克塔治疗公司 | 低聚物-芳氧基-取代的丙胺共轭物 |
| EP2133072A1 (fr) | 2008-06-13 | 2009-12-16 | KRKA, D.D., Novo Mesto | Compositions orales pharmaceutiques gastro-résistantes comportant du duloxétine ou ses dérivés pharmaceutiques acceptables |
| CN101613347B (zh) | 2008-06-23 | 2012-07-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物及其医药用途 |
| HU230480B1 (hu) * | 2008-07-25 | 2016-07-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás N-metil-ariloxi-propánamin származékok előállítására |
| SI2329013T1 (sl) | 2008-08-27 | 2016-03-31 | Codexis, Inc. | Polipeptidi ketoreduktaze za proizvodnjo 3-aril-3-hidroksipropanamina iz 3-aril-3-ketopropanamina |
| US8288141B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| CZ304602B6 (cs) | 2009-09-02 | 2014-07-30 | Zentiva, K. S. | Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) |
| EP2377525A1 (fr) | 2010-03-26 | 2011-10-19 | Laboratorios del Dr. Esteve S.A. | Granulés entériques à la duloxétine |
| WO2011128370A1 (fr) | 2010-04-13 | 2011-10-20 | Krka, D.D., Novo Mesto | Synthèse de duloxétine et/ou de ses sels pharmaceutiquement acceptables de celle-ci |
| WO2012024397A2 (fr) | 2010-08-17 | 2012-02-23 | Albany Molecular Research, Inc. | Dérivés 2,5-méthano- et 2,5-éthano-tétrahydrobenzazépine et utilisation de ceux-ci pour bloquer le recaptage de la norépinéphrine, de la dopamine, et de la sérotonine |
| EP2508519A1 (fr) * | 2011-04-07 | 2012-10-10 | Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A. | Procédé pour la préparation de duloxétine et de son sel hydrochlorure |
| GR1007725B (el) | 2011-10-17 | 2012-10-18 | Φαρματεν Αβεε, | Μεθοδος δια την παρασκευη υδροχλωρικης ντουλοξετινης υψηλης καθαροτητας |
| PL224543B1 (pl) | 2013-08-21 | 2017-01-31 | Pabianickie Zakłady Farm Polfa Spółka Akcyjna | Dojelitowa tabletka duloksetyny |
| US9668975B2 (en) | 2014-10-14 | 2017-06-06 | PharmaDax Inc. | Method of preparing drug agglomerate |
| CN105777706B (zh) | 2014-12-25 | 2019-08-23 | 江苏恩华药业股份有限公司 | 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 |
| JP2016222628A (ja) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | デュロキセチン塩酸塩の製造方法 |
| JP6182183B2 (ja) * | 2015-07-07 | 2017-08-16 | 東和薬品株式会社 | デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法 |
| CN106349211B (zh) * | 2016-08-26 | 2020-10-16 | 江苏恩华药业股份有限公司 | 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用 |
| EP3339304A1 (fr) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nouveaux dérivés de quinoléine et d'isoquinoléine destinés à traiter la douleur et des états liés à la douleur |
| EP3838899A4 (fr) | 2018-08-17 | 2022-02-16 | Shanghai Leado Pharmatech Co. Ltd. | Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, et utilisation associée |
| EP3971181A4 (fr) * | 2019-05-16 | 2023-11-08 | Shanghai Leado Pharmatech Co. Ltd. | Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, forme cristalline et utilisation associée |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2842555A (en) * | 1954-07-27 | 1958-07-08 | Burroughs Wellcome Co | Method of preparing quaternary salts of amino carbinols |
| AT255400B (de) * | 1965-03-22 | 1967-07-10 | Chemie Linz Ag | Verfahren zur Herstellung von neuen basischen Äthern |
| US3423510A (en) * | 1966-08-31 | 1969-01-21 | Geigy Chem Corp | 3-(p-halophenyl) - 3 - (2'-pyridyl-n-methylpropylamine for the treatment of depression |
| US4018895A (en) * | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
| FR2482956A1 (fr) * | 1980-05-22 | 1981-11-27 | Synthelabo | Cyclohexylalkylamines, leurs procedes de preparation et leur application en therapeutique |
-
1986
- 1986-12-18 KR KR860014449A patent/KR880007433A/ko active Pending
-
1987
- 1987-12-17 DK DK198706648A patent/DK174599B1/da not_active IP Right Cessation
- 1987-12-17 CA CA000554601A patent/CA1302421C/fr not_active Expired - Lifetime
- 1987-12-17 AU AU82660/87A patent/AU591007B2/en not_active Expired
- 1987-12-17 EG EG731/87A patent/EG18230A/xx active
- 1987-12-17 SU SU874203804A patent/SU1598865A3/ru active
- 1987-12-17 IL IL84863A patent/IL84863A/xx not_active IP Right Cessation
- 1987-12-17 PT PT86389A patent/PT86389B/pt unknown
- 1987-12-17 ZA ZA879472A patent/ZA879472B/xx unknown
- 1987-12-18 DE DE200512000002 patent/DE122005000002I1/de active Pending
- 1987-12-18 NZ NZ222980A patent/NZ222980A/xx unknown
- 1987-12-18 ES ES87311181T patent/ES2019949B3/es not_active Expired - Lifetime
- 1987-12-18 DE DE19873765919 patent/DE122005000002I2/de active Active
- 1987-12-18 DE DE8787311181T patent/DE3765919D1/de not_active Expired - Lifetime
- 1987-12-18 AT AT87311181T patent/ATE57924T1/de active
- 1987-12-18 EP EP87311181A patent/EP0273658B1/fr not_active Expired - Lifetime
- 1987-12-18 IE IE873449A patent/IE873449L/xx not_active IP Right Cessation
- 1987-12-18 CN CN87108175A patent/CN1019113B/zh not_active Expired
- 1987-12-18 KR KR1019870014449A patent/KR960003808B1/ko not_active Expired - Lifetime
- 1987-12-18 AR AR87309638A patent/AR243868A1/es active
- 1987-12-18 HU HU875863A patent/HU206309B/hu unknown
- 1987-12-18 JP JP62322617A patent/JP2549681B2/ja not_active Expired - Lifetime
- 1987-12-18 PH PH36267A patent/PH26556A/en unknown
- 1987-12-18 MX MX984587A patent/MX9845A/es unknown
-
1990
- 1990-12-18 GR GR90401079T patent/GR3001207T3/el unknown
-
1992
- 1992-11-04 SG SG1149/92A patent/SG114992G/en unknown
-
1993
- 1993-07-22 HK HK696/93A patent/HK69693A/en not_active IP Right Cessation
- 1993-10-10 CY CY1682A patent/CY1682A/xx unknown
-
2005
- 2005-01-26 LU LU91131C patent/LU91131I2/fr unknown
- 2005-01-27 CY CY200500001C patent/CY2005001I1/el unknown
- 2005-01-31 NL NL300171C patent/NL300171I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91131I2 (fr) | Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine. | |
| LU90866I2 (fr) | Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine | |
| LU90297I2 (fr) | Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate | |
| LU91452I2 (fr) | "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" | |
| LU91147I2 (fr) | Pemetrexed et ses sels pharmaceutiquement acceptables. | |
| LU90069I2 (fr) | Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) | |
| LU91599I2 (fr) | Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene) | |
| NO2001009I1 (no) | Kvetiapin og farmasøytisk akseptable salter derav | |
| FR2592048B1 (fr) | Inhibiteurs d'ureido-renine, a action therapeutique | |
| LU91650I2 (fr) | Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin | |
| ZA883602B (en) | Medicament | |
| LU90829I2 (fr) | Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables | |
| LU90710I2 (fr) | Galanthamine ou ses sels d'addition acides | |
| LU90712I2 (fr) | Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables | |
| LU91039I2 (fr) | Proteq flu et ses dérivés pharmaceutiquement acceptables | |
| LU90865I2 (fr) | Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine | |
| NZ219644A (en) | Crystalline 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride and pharmaceutical compositions | |
| IT1197038B (it) | Composizione farmaceutica ad attivita' analgesica | |
| LV5765B4 (lv) | (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats | |
| BR9100519A (pt) | Composto,composicao farmaceutica,metodo para inibicao de colinesterase em um mamifero e metodo para melhorar a memoria ou tratar ou prevenir a doenca de alzheimer | |
| FI883338A7 (fi) | Doksorubisiinihydrokloridin vesiliuoksia | |
| LU90110I2 (fr) | Penciclovir et ses dérivés pharmaceutiquement acceptables | |
| FI943875L (fi) | 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja | |
| DK47788D0 (da) | 14,15-substituerede lanosteroler og fysiologisk acceptable salte deraf og deres anvendelse som farmaceutika | |
| IT1199320B (it) | 8-azaxantine alchilaminoalchil o eterociclilalchil sostituite sul nucleo triazolico,loro sali fisiologicamente accettabili,loro composizioni farmaceutiche ad attivita'antibroncospastica e relativo procedimento di preparazione |